Tc biopharm regains compliance with nasdaq listing rule 5550(b)

Edinburgh, scotland , aug. 15, 2024 /prnewswire/ -- tc biopharm (holdings) plc ("tc biopharm" or the "company") (nasdaq: tcbp) a clinical stage biotechnology company developing platform allogeneic gamma-delta t cell therapies for cancer and other indications, today announced that the company has regained compliance with the nasdaq stock market listing rule 5550(b) which will maintain the listing of the company's american depositary shares on the nasdaq global select market. on may 24, 2024, the company received written notification from the listing qualifications staff of the nasdaq stock market, llc ("nasdaq") indicating that the company was not in compliance with the minimum stockholders' equity requirement, as of march 31, 2024.
NDAQ Ratings Summary
NDAQ Quant Ranking